Login to Your Account



Eylea generates cash for Regeneron, but Praluent plodding

By Marie Powers
News Editor

Thursday, May 5, 2016

Analysts and investors found plenty to like in first quarter earnings from Regeneron Pharmaceuticals Inc., which beat consensus revenue forecasts with approximately $1.2 billion in global sales, including a 44 percent increase in U.S. and global net sales of Eylea.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription